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The generation of toxic non-native protein conformers has emerged as a unifying thread among disorders such as Alzheimer’s disease,
Parkinson’s disease, and amyotrophic lateral sclerosis. Atomic-level detail regarding dynamical changes that facilitate protein aggre-
gation, as well as the structural features of large-scale ordered aggregates and soluble non-native oligomers, would contribute signifi-
cantly to current understanding of these complex phenomena and offer potential strategies for inhibiting formation of cytotoxic
species. However, experimental limitations often preclude the acquisition of high-resolution structural and mechanistic information
for aggregating systems. Computational methods, particularly those combine both all-atom and coarse-grained simulations to
cover a wide range of time and length scales, have thus emerged as crucial tools for investigating protein aggregation. Here we
review the current state of computational methodology for the study of protein self-assembly, with a focus on the application of
these methods toward understanding of protein aggregates in human neurodegenerative disorders.
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Introduction
The transition of native proteins to partially unfolded and aggre-
gated species has been implicated in numerous human neurode-
generative disorders. In healthy individuals, the formation of
potentially toxic aggregates is counteracted by various quality
control mechanisms, including endoplasmic reticulum-associated
degradation and the activity of chaperones that process unfolded,
misfolded, and aggregated proteins (Barral et al., 2004). In condi-
tions of stress or in aged individuals, insufficient capacity of quality
control mechanisms may allow aggregate formation to predomin-
ate and, eventually, to cross a pathogenic threshold. However, ag-
gregation can also occur in the absence of excessive cellular stress,
even in cases where the native state of a protein is highly thermo-
dynamically favorable (Chi et al., 2003). Aggregation propensity
also depends on subcellular localization of a protein and its acces-
sibility to the various quality control mechanisms that maintain
proteostasis (Monsellier et al., 2008). Therefore, differences in
both native structures and cellular microenvironments of
intrinsically disordered proteins and peptides, folded cytosolic
proteins, and membrane proteins underlie their widely varying
aggregation propensities (Linding et al., 2004; Monsellier et al.,
2008).
Protein aggregates are found in both fibrillar (ordered) and
amorphous (disordered) forms. One of the most common structural
features found in ordered protein aggregates is the amyloid fold
(Toyama and Weissman, 2011). Amyloid fibrils contain a character-
istic cross-b architecture, which consists of b-strands running par-
allel to each other, but perpendicular to the direction of fibril
extension (Figure 1A) (Eanes and Glenner, 1968; Jahn et al.,
2010; Qiang et al., 2012). Amyloid aggregates can exhibit various
gross morphologies, such as twisted ribbons, twisted ropes,
sheets, and tubes, based on differing arrangements of protofibril-
lar units (Stromer and Serpell, 2005). Although the common pro-
pensity of multiple aggregation-prone proteins to form amyloid is
well established, there is an emerging view that neurotoxicity
related to protein aggregation occurs mainly in lower-order disor-
dered oligomers (soluble assemblies larger than the native oligo-
meric state that may be pre-fibrillar intermediates or species not
on the fibrillization pathway; examples of oligomers, protofibrils,
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and fibrils of amyloid beta (Ab) peptide are shown in Figure 1B)
(Uversky, 2010; Denny et al., 2013). One of the mechanisms
demonstrated to facilitate early stages of aggregation in associ-
ation with membranes, which can result in membrane disruption
and subsequent cell death (Aisenbrey et al., 2008). During the
process of protein misfolding at the surface of a membrane, pre-
fibrillar oligomers form non-specific ion channels (Figure 1C)
(Quist et al., 2005); the resultant alteration of membrane perme-
ability disrupts ion homeostasis, causing mitochondrial dysfunc-
tion and impaired synaptic transmission, among other neurotoxic
consequences (Kagan, 2006). Conformational features of disor-
dered and pre-fibrillar oligomers of various neurodegeneration-
linked proteins are discussed in more detail in the latter half of
the review.
Computational methods for studying protein misfolding and
aggregation
Computational models, especially when combined with experi-
mental approaches, are increasingly useful for the characterization
of changes in protein dynamics and identification of rare molecular
events that lead to aggregation (Sharma et al., 2008). In this
section, we discuss computational strategies that are commonly
employed to study protein aggregation, starting with algorithms
that predict aggregation propensity on the basis of amino acid
Figure 1 Diverse morphologies of protein aggregates. (A) The characteristic amyloid cross-b structure, as seen in a fibril model of the Iowa mutant
(D23N) of Ab40 (PDB ID: 2lnq (Qiang et al., 2012)). Individual polypeptide chains are colored differently. (B) From left to right: transmission electron
microscopy images of Ab42 oligomers, protofibrils, and fibrils. Reprinted by permission from Ahmed et al. (2010), copyright 2010 Macmillan
Publishers Ltd. (C) Atomic force microscopy (AFM) images of Ab40 (left) and a-synuclein (middle) incubated with lipid bilayers. Inset shows a
lipid bilayer in the absence of peptide/protein. Scale bar, 100 nm. At right, high-resolution AFM images (image size: 25 nm) showing individual
pores formed by Ab40 anda-synuclein within lipid bilayers. Reprinted from Quist et al. (2005), copyright 2005 National Academy of Sciences, USA.
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sequence alone or in the context of protein tertiary structure. We
then discuss methods for simulating protein aggregation and mod-
eling aggregate structures using molecular dynamics (MD) simula-
tions, including the incorporation of strategies to reduce the
computational burden of simulations involving large polypeptides
and long time scales.
Assessment of sequence determinants of protein aggregation
The question of how amino acid composition influences aggre-
gation propensity is highly relevant to protein design, as well as
to our understanding of protein evolution and the pathogenicity
of certain amino acid substitutions. Given the fact that hydrophobic
interactions are a major driving force of protein self-assembly, it is
expected that increased hydrophobic content in a peptide would
lead to increased aggregation propensity, while a net charge on
the peptide would impede aggregation. Also, with the evidence
for common cross-b architecture among amyloid fibrils of diverse
proteins (Nelson et al., 2005), a stretch of amino acids with
enhanced propensity to adopt b-strand secondary structure
would be expected to promote formation of fibrils. Such physico-
chemical properties of amino acids are the basis of most of the algo-
rithms that predict either the rate or propensity of aggregation of
different regions of a protein.
Predictors based on overall protein composition. One of the first
attempts to rationally predict the effect of protein sequence on its
aggregation propensity was based on the prediction of the effect of
a point mutation on the aggregation kinetics of a protein (Chiti
et al., 2003). This method was based on fitting the coefficients of
an empirical formula with a set of existing data for the aggregation
kinetics of 50 point mutants of human muscle acylphosphatase
(AcP), as compared with the wild-type protein (Chiti et al., 2003).
The empirical formula was a linear equation incorporating the
change in hydrophobicity, net charge, and helix-b-sheet conver-
sion propensity upon mutation. This is a simplistic model since it
treats protein properties as a simple sum, without accounting for
position of the mutation in the structure. Additionally, two terms
of the three-term equation, hydrophobicity and net charge, are
highly dependent on each other. Even with these limitations, pre-
dictions of the changes in aggregation rate associated with 27
mutations in a variety of both disease-associated and model pro-
teins obtained using this model had statistically significant correl-
ation with experimental values. This study highlights the role of
physicochemical properties of amino acids in determining, to a
large extent, the differences in aggregation rate. The two limita-
tions of this model, namely interdependent terms and fitting of
free parameters, were overcome in a more sophisticated model
from the Caflisch group (Tartaglia et al., 2004). Depending on the
type of mutation (e.g. polar to apolar or apolar to polar), the
terms of their equation included changes in aromaticity, dipole
moment, ratio of accessible surface area, and b-sheet propensity.
This equation is more complicated than the simple linear relation-
ship of Chiti et al. but does not have redundant terms and, import-
antly, does not have free parameters that must be obtained from
fitting the equation to a training set. The model of Chiti et al. was
extended to predict absolute aggregation rate by incorporating ex-
trinsic factors like ionic strength and pH at which aggregation
occurs in vitro (DuBay et al., 2004). Similarly, the updated model
from the Caflisch group can also predict absolute aggregation
rates (Tartaglia et al., 2005). The models described thus far all con-
sider the starting state of the protein to be denatured.
Predictors of peptides in amyloidogenic proteins. These types of
predictors are based on the assumptions of a well-folded starting
state and the amyloidogenic potential of a peptide within a
protein instead of just a sum over the entire protein. TANGO
(Fernandez-Escamilla et al., 2004) is one of the models incorporat-
ing these criteria. Instead of a simple linear equation for the entire
protein, the TANGO algorithm is based on the assumption that a
given amino acid position in a protein can assume four possible
states: helix, turn, unfolded, and b-aggregated. The propensity of
a particular residue to exist in each state is based on its secondary
structure propensity, solvation penalty and charge–charge inter-
actions. TANGO calculates the partition function of these different
states for each residue, assuming that the probability of one poly-
peptide chain having more than two amyloidogenic regions is neg-
ligible. This assumption limits the ability of TANGO to estimate
aggregation propensities of proteins larger than 50 amino acids.
To address the fact that the folded state is the starting point of ag-
gregation, the stability of the folded state is taken into consider-
ation in the TANGO algorithm using Fold-X (Guerois et al., 2002)
calculations. For practical purposes, TANGO is more useful for iden-
tifying whether a protein is likely to aggregate, rather than predict-
ing absolute aggregation rates. Given these caveats, in benchmark
tests of disease-associated proteins and their mutants, TANGO was
successful in predicting the stretches of these proteins that were
experimentally known to be prone to aggregation. The latest exten-
sion of this approach is WALTZ (Maurer-Stroh et al., 2010), which,
among other developments, significantly expanded the peptide
training set in order to reduce biases in the original algorithm
that were attributed to the smaller training set. In the same class
of predictors of aggregation-prone stretches of amino acids in a
protein, there are several additional algorithms, including an ex-
tension of the original method of Chiti et al. (as surveyed by Belli
et al. (2011)). There even exists a server that combines the
results of several of these algorithms and provides a consensus
prediction (Hamodrakas et al., 2007).
Predictors that consider tertiary structure of an amyloid. TANGO,
WALTZ, and a similar program, Zyggregator (Tartaglia and
Vendruscolo, 2008), implicitly consider tertiary structure by in-
corporating protein stability measurements. However, there are
two classes of algorithms that explicitly consider structure of the
final amyloid. One option to obtain this information is to perform
coarse-grained MD simulations (discussed below) of peptides or
proteins to estimate their amyloidogenicity (Cecchini et al., 2006;
Ding et al., 2012). Another option is to assume the cross-barchitec-
ture (Figure 1A) described in published models of amyloid fibrils
and ‘thread’ the sequence of a protein onto this template structure,
in order to observe whether certain regions are able to stably adopt
this conformation (Thompson et al., 2006; Trovato et al., 2006;
Zhang et al., 2007). The advantage of these methods over the
purely sequence-based methods described above is that they expli-
citly account for subtle structural features of amyloid fibrils, includ-
ing twist in theb-strands and tertiary contacts between amino acids
resulting from electrostatic and steric effects. However, the super-
iority of these methods over the sequence-based methods is not
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clear, mainly because the actual structures of some amyloids may
not be identical to the cross-b models assumed in these methods.
Khare et al. (2005a) applied a hybrid approach, separately examin-
ing sequence and structural determinants of the per-residue aggre-
gation propensity of Cu, Zn superoxide dismutase (SOD1).
Overlapping heptapeptide fragments spanning the entire SOD1 se-
quence were threaded onto idealized dimeric and tetrameric
b-strand templates and conformational free energy was calculated
following MD simulations, in order to assess the energetic favor-
ability of a given region of the SOD1 adopting an amyloidogenic
conformation. To identify ‘hot spots’ of SOD1 amyloidogenicity in
the context of misfolding of the native dimeric structure, in silico
conditions under which SOD1 forms domain-swapped oligomers
were used to identify regions of protein structure that participate
in non-native intermonomer contacts. Evaluating amyloidogenicity
in these two distinct approaches implicated the same regions of
SOD1, suggesting that aggregation ‘hot spots’ in this protein
arise from multiple factors: the inherent propensity of certain se-
quence regions to adopt b-strand-rich conformations, as well as
the position of these regions within the context of the native
protein as it misfolds.
Applications and limitations. An important application of the
methods described above is the ability to scan proteomes of
several organisms to observe the prevalence of amyloidogenic
sequences throughout evolution. Such studies have yielded inter-
esting conclusions: (i) evolution disfavors the adoption of amyloi-
dogenic sequences by intrinsically disordered proteins (Linding
et al., 2004; Chen and Dokholyan, 2008); (ii) to allow hydrophobic
cores, stably folded proteins must also tolerate amyloidogenic
sequences (Linding et al., 2004); (iii) stably folded proteins circum-
vent amyloidogenic sequences by having ‘gatekeeper’ residues
like glycine, proline, and charged amino acids near the amyloido-
genic stretches, which counteract their high aggregation propen-
sities (Rousseau et al., 2006); and (iv) proteins that form
homooligomeric complexes have lower aggregation propensities
than proteins that do not exist as homooligomers (Chen and
Dokholyan, 2008). Furthermore, proteins that are essential to or-
ganismal fitness have lower aggregation propensities than non-
essential proteins. Another application of intense interest is the
use of these algorithms to predict mutations that reduce aggrega-
tion propensities of specific proteins (Fowler et al., 2005). This ap-
plication is especially useful in designing mutations to stabilize
protein-based biotechnological products, including therapeutic
agents.
There has been a reasonable degree of progress made toward
the prediction of sequence determinants of aggregation.
However, there are significant challenges that remain. The best cor-
relations between experiments and predictions can be attributed to
simple physicochemical properties. For example, some of the best
predictions involve introduction of charged residues. These
methods also suffer from excessive false positive predictions,
which are accompanied by the fact that even the most sophisti-
cated algorithm does not take into account the protein structure/
sequence as a whole. Thus, at this stage, we can conclude that
simple rules may explain a significant portion of protein aggrega-
tion mechanisms, but to reach more thorough understanding, ag-
gregation must be studied in the context of the tertiary structure
of the entire protein. To enable such studies, significant advance-
ments in computational resources and/or significant improve-
ments in algorithms to simulate protein conformational states
are essential.
Modeling of protein aggregate structures with MD
Structural and dynamic properties of protein states populated
along the aggregation pathway are important for our understand-
ing of misfolding and aggregation mechanisms, and also for the de-
velopment of strategies for therapeutic inhibition. Although the
aggregate structures of several short peptide segments of amyloi-
dogenic proteins have been solved by X-ray crystallography
(Nelson et al., 2005; Sawaya et al., 2007; Neudecker et al.,
2012), the structures of aggregates and pre-fibrillar intermediates
of many misfolding-prone proteins are not known. These inter-
mediate states are often transient in nature, making them difficult
to capture and thus challenging to characterize experimentally. As
a result, atomic structures of protein aggregates are a major
subject of computational modeling studies (Ma and Nussinov,
2006).
MD simulations utilize the input of a set of spatial coordinates of
the system of particles (atoms, amino acid residues, or their equiva-
lents) to evaluate the potential energy of the system. The tradition-
al simulation engine iteratively solves Newton’s equations of
motion over small time steps. The output of the simulation is a tra-
jectory of spatial coordinates describing the behavior of the system
over time, like a movie of a virtual experiment. Direct observation of
the formation of oligomers is currently not achievable using
all-atom MD simulations due to the requirement of extensive sam-
pling. To increase computational efficiency of biomolecule simula-
tions, researchers have developed discrete molecular dynamics
(DMD), an event-driven algorithm in which adaptive discretization
of the potential function is combined with optimized treatment of
hydrogen bonds and implicit solvent interactions (Dokholyan
et al., 1998; Ding et al., 2008; Dagliyan et al., 2011; Shirvanyants
et al., 2012). DMD has been used to study conformational dynamics
and molecular mechanisms of self-assembly for a wide variety of
proteins and peptides (Ding et al., 2002, 2005a, 2012; Peng
et al., 2004; Khare et al., 2005b).
Another method for reducing the computational burden of oligo-
merization simulations is to start simulations from experimentally
obtained structures. For example, Jang et al. (2010) utilized struc-
tures of the Ab peptide from NMR and electron microscopy in MD
simulations to examine the conformations of b-barrel channels
that are proposed to be toxic. Using 12-, 16-, and 20-mer structures,
the authors obtained results similar to those found using atomic
force microscopy (AFM), emphasizing the possible heterogeneity
of structures formed by Ab oligomers. The near-native structure
and dynamics of oligomers and pre-fibrillar aggregates can be
explored using experimentally solved structures, but in order to
observe de novo aggregation and other events occurring on
longer time scales, current limits on computational power dictate
that researchers simplify their representation of these structures.
Coarse-graining for complex systems
MD simulations with all-atom modeling have been used to study
the early stages of protein misfolding and aggregation (as reviewed
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by Straub and Thirumalai (2010)). However, the typical time
scales accessible by atomistic simulations are 100 nsec to
msec, or msec with state-of-the-art, hardware-accelerated
supercomputers (Lindorff-Larsen et al., 2011); these time scales
are far shorter than the days, years, or even decades sometimes
required for protein aggregation. The propensity to aggregate
appears to be a sequence-independent property of all polypeptide
chains (Dobson, 1999) that is governed by fundamental interac-
tions (such as hydrophobicity and electrostatics); therefore,
coarse-grained simulations with simplified representations of pro-
teins represent a tractable method for recapitulating physiological-
ly relevant aggregation events (reviewed by Wu and Shea (2011)).
Coarse-graining of a system simplifies groups of atoms into beads,
with each bead usually representing more than one atom: for in-
stance, a bead could represent an amino acid residue, part of a
residue, or a particular chemical group. In exchange for the reduc-
tion in accuracy due to simplification, coarse-grained simulations
have the capability to reach longer time and length scales on
account of the fewer particles and therefore fewer calculations ne-
cessary at each time step. Some commonly used coarse-grained
protein models include MARTINI (Marrink et al., 2007) and PRIME
(Voegler Smith and Hall, 2001).
A disadvantage of the coarse-graining of protein systems is the
difficulty of modeling large changes in secondary structure,
which are common in processes of misfolding and aggregation.
To address this issue, researchers have introduced phenomeno-
logical coarse-grained models, which represent specific peptides
based on steps in their misfolding processes. Pellarin et al.
(2007) utilized a two-state peptide model, comprising an amyloid-
competent and an amyloid-protected state, with Langevin dynam-
ics to simulate an amphipathic peptide. By varying only the relative
stabilities of the two states, the authors demonstrated control over
the roughness of the free energy surface and the heterogeneity of
the fibril elongation pathway. Increasing the energy gap between
the two states, equivalent to decreasing theb-aggregation propen-
sity, roughened the free energy surface, creating additional inter-
mediates along the elongation pathway.
In addition to phenomenological models, physics-based coarse-
grained models are widely employed for studying protein aggrega-
tion. These models rely on physical force fields to define the energy
of the system, instead of assigning parameters meant to mimic ex-
perimental observations, and are therefore more applicable to gen-
eralized real-world systems. Physics-based models have been used
to assess the effect of b-sheet propensity on peptide aggregation
with a three-bead model (Bellesia and Shea, 2009), and to reveal
the amyloidogenesis mechanisms of Ab peptides (Peng et al.,
2004) and Src SH3 domain (Ding et al., 2005b) using two-bead
models.
Multi-scale approaches that bridge coarse-grained and all-atom
simulations
Molecular modeling with fully atomistic representation provides
the most accurate description of the structure and dynamics of the
molecular system. However, all-atom simulations have limited
ability to reach long time scales and large polypeptide length
scales because they are required to compute all of the detailed
interactions and dynamics of the system. For this reason,
all-atom simulations have been mainly applied to study early
events of protein misfolding and aggregation. On the other hand,
coarse-grained simulations with simplified representation of the
molecular system have the ability to reach longer time scales and
model larger systems, but with the drawback of less accurate de-
scription of the molecular systems. Multi-scale modeling
approaches have been proposed as a means of combining both
all-atom and coarse-grained simulations in order to cover a wide
range of time and length scales. The challenges of multi-scale mod-
eling include the choice and development of a coarse-grained force
field, the inter-conversion of molecular models with different reso-
lutions, and the coupling between simulations of different scales.
Multi-scale modeling has allowed the investigation of the struc-
ture and dynamics of lipid membranes, proteins, and DNA (as
reviewed by Ayton et al. (2007) and Tozzini (2010)). These
methods often involve conformational sampling with coarse-
grained simulations, all-atom reconstruction, and subsequent en-
ergetic evaluation with atomistic simulations (Heath et al., 2007;
Samiotakis et al., 2010). Similar multi-scale modeling approaches
have also been applied to study protein misfolding and aggrega-
tion. For example, coarse-grained simulations are often used to
generate an ensemble of possible aggregate conformations to
serve as starting structures for all-atom simulations, allowing the
evaluation of the thermodynamic viability and structural features
of different assemblies (Urbanc et al., 2004a; Ding et al., 2005a).
This approach was used to identify atomic-level differences in
dimers of Ab40 and those of the more toxic Ab42 alloform (Barz
and Urbanc, 2012). Multi-scale methods can also be employed in
the reverse order: all-atom simulations were used to analyze the
structural elements in SOD1 that are prone to form the core of fibril-
lar aggregates, and this information was incorporated into subse-
quent coarse-grained simulations to model the formation of large
SOD1 aggregates (Ding et al., 2012). Therefore, by combining high-
accuracy atomistic simulations with coarse-grained simulations
that are able to sample long time scales, multi-scale modeling
approaches offer the opportunity to cover a wide range of time
and length scales, which is important for bridging the gaps
between experimental observations and underlying molecular
systems.
Application of computational methods to the study of protein
aggregation in human diseases
Ab and Alzheimer’s disease
Ab is a peptide of variable length (36–43 residues) that is formed
by the sequential cleavage of Ab precursor protein (APP) byb- and
g-secretases in the ER lumen and transmembrane domain (TMD),
respectively (Golde et al., 1992; Chiti and Dobson, 2006). The
most abundant Ab peptides derived from the TMD of APP are
Ab40 and the toxic Ab42 (Figure 2A), where Ab40 is 10 times more
populated than Ab42 (Näslund et al., 1994). Both Ab40 and Ab42
can populate a range of oligomeric states, but Ab42 is more
prone to adopt transient oligomeric conformations that rearrange
to form protofibrils (Bitan et al., 2003). Unlike monomeric Ab42,
these early soluble oligomers and protofibrils of Ab42 are sug-
gested to be the major contributors to the onset of neurodegenera-
tion in Alzheimer’s disease (AD) (Chiti and Dobson, 2006). As in
other protein aggregation diseases, protein misfolding is thought
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to be the initiating process of AD pathology, and can be induced by
destabilizing conditions such as low pH, high temperature, and
amino acid substitution (Bucciantini et al., 2002; Dobson, 2003).
The assembly of Ab into soluble oligomers and amyloid fibrils
has been investigated with various experimental methods (Chiti
and Dobson, 2006); however, it is still experimentally challenging
to characterize oligomerization-triggering events at the atomic
level due to the transient equilibria between various orders of oli-
gomers. Therefore, computer simulations can provide experimen-
tally inaccessible insights into early Ab oligomerization steps
that could be targeted for drug discovery efforts.
MD simulations have been employed to probe the structural fea-
tures of Ab oligomers and fibrils, as well as the key interactions me-
diating their assembly. Based on MD simulations and solid-state
NMR experiments, a structural model of amyloid fibrils formed by
Ab40 peptides was built (Petkova et al., 2002). In this fibril model,
the first 10 residues are disordered while residues 12–24 and 30–
40 form parallel b-sheets, which interact with each other through
side-chain interactions involving residues 25–29. Residues Asp-23
and Lys-28 in the core form salt bridges that stabilize the cross-b
unit, which consists of a double-layered b-sheet structure with
hydrophobic core and face (Petkova et al., 2002; Baumketner and
Shea, 2007). MD simulations have revealed the effects of Ab40 on
the competence of Ab42 to form fibrils: b strand content of the
Ab42 monomer was found to decrease in the presence of Ab40,
leading to increased flexibility of the Asp-23-Lys-28 salt bridge and
residues 18–33 of Ab42, thus decreasing fibril stability (Viet and
Li, 2012). Calculations from DMD simulations indicated no signifi-
cant free energy difference between formation of Ab40 dimers and
Ab42 dimers, suggesting that thermodynamically stable planar
b-strand dimers do not initiate Ab oligomerization (Urbanc et al.,
2004a). The distinct oligomer formation of Ab40, Ab42, their versions
containing anAD-causing substitution (E22G), and theirN-terminally
truncated versions were investigated with a four-bead DMD model
(Urbanc et al., 2004b, 2010; Meral and Urbanc, 2013). Consistent
with experimental findings (Bitan et al., 2003), these computational
studies revealed that two C-terminal residues in Ab42 cause the dif-
ference in oligomer size distribution between Ab40 and Ab42,
whereas N-terminally truncated versions show increased aggrega-
tion propensity. Furthermore, Yun et al. (2007) showed that
Figure 2 Primary structures of neurodegeneration-linked proteins and peptides discussed in this review. (A) Amino acid sequence of Ab42; the
sequence of Ab40 is identical except for the C-terminal isoleucine and alanine. (B) Sequence of the protein product of an HTT exon 1 variant
with 21 CAG repeats. The site of the variable-length polyQ tract is shaded. (C) Sequence of SOD1, shaded to indicate amino acids that participate
in the intramolecular disulfide bond, coordination of Cu2+ or Zn2+, and formation of the homodimer, steps in SOD1 maturation that contribute to
the stability of the native state. (D) Sequence and domains of a-synuclein, shaded to indicate the N-terminal domain, containing multiple con-
served imperfect KTKEGV repeats (enclosed in boxes), and the non-Ab component of plaque (NAC) domain, which is characterized by a high
content of hydrophobic residues and promotes a-synuclein aggregation. The N-terminal and NAC domains form transient a helical structures
and are involved in binding to membranes (Breydo et al., 2012). The C-terminal acidic domain is indicated by dark shading; this domain contains
a high content of proline, aspartate, and glutamate residues and is the site of numerous interactions with proteins and ligands such as dopamine
and its analogs, calcium, copper, and iron (Breydo et al., 2012). Asterisks mark sites of amino acid substitutions linked to AD (A), HD (B), ALS (C),
and PD (D); substitution sites reflect entries from the Human Gene Mutation Database (http://www.hgmd.org), the Alzheimer Disease
and Frontotemporal Dementia Mutation Database (http://www.molgen.ua.ac.be/ADMutations/), and the ALS Online Genetics Database
(http://alsod.iop.kcl.ac.uk/) as of January 2014.
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electrostatic interactions facilitate oligomerization of both Ab40 and
Ab42 into trimers and tetramers, while Ab42 can also form nonamers
and tetradecamers due to its extended C-terminus via a quasi-stable
turn. The crystal structure of an Ab18– 41 tetramer (Streltsov et al.,
2011) supported the oligomeric structures suggested in these
DMD studies.
In addition to elucidating Abaggregation mechanisms and struc-
tures of oligomers and fibrils, results from computational studies
have been used to propose a number of therapeutic approaches
for blocking Ab aggregation. One strategy for blocking Ab aggrega-
tion is the generation of peptides that mimic the structure of a
portion of Ab, such that they will bind to a growing fibril but
cannot serve as a template for further extension. Fibril formation
was found to be reduced by chemically-modified pentapeptides
that mimic Ab17 – 20 (LVFF), but act as b-sheet breakers
(Permanne et al., 2002; Adessi et al., 2003). In another study,
docked conformations of Ab17 – 20-mimicking peptides were used
to design 3D-pharmacophores for virtual screening. Based on
docking scores and physicochemical features, 16 diverse small
molecule compounds were selected for experimental tests. At 2–
3 mM concentrations of the selected hit compound, Abaggregation
was reversed in vitro and in vivo (Chen et al., 2009). The relation-
ship between aggregation rate and binding affinity of the b-sheet
breaker peptides KLFVV and LPFFD was investigated with
all-atom MD simulations, which showed that KLVFF is less effective
than LPFFD at preventing aggregation of Ab16 – 22 peptides.
Analysis of the relative affinities of these two peptides using the
Molecular Mechanics Poisson–Boltzmann surface area method
revealed that the greater efficacy of LPFFD is attributable to its
higher affinity for Ab16 – 22. These simulations also showed that al-
though totalb-sheet content is elevated in the presence ofb-sheet
breaker peptides, aggregation rate is decreased due to a reduction
in b-sheet content of fibril-prone regions (Viet et al., 2011).
In light of the emerging view of Ab oligomers, as opposed to
fibrils, as primary disease-causing toxic species, computational
approaches have also focused on the therapeutic potential of tar-
geting these species. Inhibitors based on Ab peptide fragments
reduce toxic effects of Ab42 without preventing Ab42 oligomeriza-
tion; simulations with a four-bead DMD model revealed that
these peptides form large assemblies with Ab42 and reduce their
b-strand content (Urbanc et al., 2011). These results highlight
the therapeutic potential of stabilizing Ab in a relatively benign
conformation, even when the abundance of oligomers is largely un-
altered. Computational characterization of mechanisms by which
inhibitors reduce Ab toxicity, as well as of Ab folding and structures
of oligomers and aggregates, was recently reviewed by Shea and
Urbanc (2012).
Huntingtin and Huntington’s disease
The interesting transcript 15 (IT15), also called the huntingtin
gene (HTT), encodes a 350 kDa multidomain protein that is es-
sential for brain development (MacDonald et al., 1993; Reiner
et al., 2003). The protein product, huntingtin protein (htt), contains
a polymorphic glutamine/proline rich domain close to its amino-
terminus (Figure 2B) (MacDonald et al., 1993). The polymorphic
nature of the 5′ region of HTT results in a variable size of the
protein product with anomalous polyglutamine (polyQ)
expansions; the presence of htt with expanded polyQ tracts is char-
acteristic of aggregates found in neurons of Huntington’s disease
(HD) patients. HD is a late-onset autosomal-dominant neurodegen-
erative disorder characterized by acute motor dysfunction, cogni-
tive decline, and psychiatric disturbances (Landles and Bates,
2004). The age of onset of HD symptoms is inversely proportional
to the length of polyQ expansion (Bates, 2005). Although ubiqui-
tously expressed and localized to several subcellular compart-
ments, the normal function of htt has not been established due
to its lack of homology to other known proteins (Harjes and
Wanker, 2003). Roles for htt in numerous cellular processes are
suggested by its ability to bind to proteins involved in apoptosis,
vesicle transport, morphogenesis, and transcriptional regulation
(Harjes and Wanker, 2003; Li and Li, 2004). Recent reports
suggest that htt is involved in modulation of gene transcription
via direct interaction with genomic DNA (Bates, 2005).
Biochemical and biophysical studies have established that re-
gardless of length, polyQ expansions result in the formation of
aggregates with common structural features (Klein et al., 2007;
Vitalis et al., 2009). However, detailed structural information per-
taining to polyQ-htt is difficult to obtain experimentally, as even
short polyQ tracts make htt insoluble at the high concentrations
required for crystallography or NMR studies (Truant et al., 2008).
Computational approaches, on the other hand, have provided
atomistic details of the structural organization of polyQ-htt of dif-
ferent lengths and oligomeric states (Marchut and Hall, 2007).
Several structural models, including the triangular b-helix model
and the antiparallelb-sheet model, were proposed and have geom-
etries compatible with existing experimental data (Stork et al.,
2005; Esposito et al., 2008). Classical MD simulations have pro-
vided valuable insights into the stability, toxicity, folding, and
three-dimensional organization of monomeric and aggregated
polyQ-htt (Finke et al., 2004; Armen et al., 2005; Khare et al.,
2005b; Sikorski and Atkins, 2005; Stork et al., 2005; Barton
et al., 2007; Esposito et al., 2008; Lakhani et al., 2010). In addition
to MD simulations, force field-based Monte Carlo simulations have
also been employed to study the aggregation characteristics of
polyQ (Vitalis et al., 2009). Several studies have focused on the de-
pendence of the structural stability of the circularb-helix and other
possible structures on polyQ extension length (Khare et al., 2005b;
Stork et al., 2005; Marchut and Hall, 2007; Ogawa et al., 2008;
Lakhani et al., 2010; Rossetti et al., 2011). Although conflicting
views prevail, these studies are in general agreement that polyQ
extensions of 30 Qs or more impart maximal stability to the result-
ing b-helix structures (Stork et al., 2005; Merlino et al., 2006;
Ogawa et al., 2008). In contrast to these results, experimental
and computational studies have proposed and validated the forma-
tion of annular units smaller than the circular b-helix structures
(Marchut and Hall, 2006a, 2007). In addition, using enhanced sam-
pling techniques, several groups have demonstrated the depend-
ence on sequence context of the aggregation propensity of polyQ
tracts (Kelley et al., 2009; Lakhani et al., 2010).
As outlined above, atomistic details of the association of mono-
meric polyQ-htt of a given length to form mature fibrils remain a
matter of controversy. Although computational studies can
provide atomistic details of such molecular processes, they are
largely limited by the long time scales required to observe such
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events. A common methodology used to overcome this limitation is
the use of coarse-grained modeling of protein–protein interac-
tions. Simplified models of polyQ have been developed to study
their aggregation propensities (Marchut and Hall, 2006a, b,
2007). Using DMD, Barton et al. (2007) demonstrated that the for-
mation of inter-glutamine hydrogen bonds defines the dominant
interactions involved in aggregation of unfolded intermediates.
More recently, it was demonstrated using enhanced sampling tech-
niques that the amino acid sequences flanking the huntingtin
repeats influence the misfolding propensity of the polyQ-htt, in
agreement with experimental observations (Ding et al., 2008;
Lakhani et al., 2010; Shirvanyants et al., 2012). Applications
of computational methods toward understanding the molecular
mechanisms of HD are discussed by Rossetti and
Magistrato (2012).
SOD1 and ALS
The link between SOD1, a homodimeric antioxidant metallopro-
tein (Figure 2C), and amyotrophic lateral sclerosis (ALS), a
late-onset neurodegenerative disorder specifically affecting
motor function, was first discovered in the early 1990s (Rosen
et al., 1993) and over 150 mutations in the gene encoding SOD1
have since been identified in ALS patients. ALS-linked mutants of
SOD1 range from completely inactive to wild type-like in their dis-
mutase activities, with no correlation between enzymatic activity
and disease severity, but many SOD1 mutations have a common
effect of decreasing stability of the native homodimeric conform-
ation (Khare et al., 2006; Shaw and Valentine, 2007); more desta-
bilizing mutations having a tendency to cause ALS with earlier
onset and/or more rapid progression (Wang et al., 2008).
Pathophysiology of ALS, like that of other neurodegenerative
disorders, is extraordinarily complex; it is difficult to distinguish
between deleterious phenomena that initiate disease onset from
those appear subsequently. Soluble misfolded SOD1, present as
monomers and non-native dimers, trimers, and higher-order oligo-
mers (Banci et al., 2007; Gruzman et al., 2007), directly disrupts
neuronal homeostasis by interacting with components essential
to processes such as axonal transport, mitochondrial function, pro-
teasomal efficiency, and ER-associated degradation (Ferraiuolo
et al., 2011; Redler and Dokholyan, 2012). In addition to destabil-
izing mutations, SOD1 can be induced to misfold and aggregate by
non-genetic factors such as oxidation, which induces wild-type
SOD1 to adopt similar conformations to that of ALS-linked
mutants and also exacerbates the destabilizing effects of some
mutations (Bosco et al., 2010; Proctor et al., 2011; Mulligan
et al., 2012). SOD1 aggregation, particularly the formation of
soluble oligomers, is thus considered to be a potentially wide-
spread factor in ALS pathogenesis.
MD simulations have been instrumental in studying the contribu-
tions of individual residues to SOD1 stability, folding, and misfold-
ing. DMD was used to identify residues most essential to the
thermodynamic stability and two-state folding kinetics of wild-type
SOD1 (Khare et al., 2003). As monomeric SOD1 containing
ALS-linked mutations and lacking bound metal ions and/or the
native intramolecular disulfide bond represent the most
aggregation-competent species, much effort has been focused
on characterization of their stability and dynamics. From
simulations of 75 ALS-linked SOD1 mutants using the explicit
solvent/implicit solvent (ES/IS) method, Khare et al. (2006) calcu-
lated the effect of each mutation on thermodynamic stability of
dimers and monomers, finding that over 90% of the mutations
studied decrease dimer stability, increase dimer dissociation pro-
pensity, or both. All-atom MD simulations with explicit solvent
also revealed a common tendency of ALS-causative mutations to
weaken the native hydrogen-bonding network by restricting corre-
lated movements between subunits in the dimer, showing the im-
portance of dynamic coupling to SOD1 stability (Khare and
Dokholyan, 2006). An altered network of hydrogen bonds was
also shown for the G37R mutant using implicit solvent MD
(Milardi et al., 2010). A4V-SOD1, in addition to exhibiting the
increased loop and active site fluctuations seen in most
ALS-linked mutants (Shipp et al., 2003; Tiwari and Hayward,
2003; Rodriguez et al., 2005; Tiwari et al., 2005), has higher
solvent exposure of Cys-111, which is susceptible to destabilizing
post-translational modification (Proctor et al., 2011; Redler et al.,
2011) and has been shown to modulate aggregation propensity
(Cozzolino et al., 2008). Results from MD simulations also indicated
that, unlike the wild-type protein, A4V forms a-sheet and a-bridge
structures that have been observed in other amyloidogenic pro-
teins (Schmidlin et al., 2009).
To determine the relative contributions of metal binding and the
native disulfide bond to SOD1 misfolding, Ding and Dokholyan
(2008) used all-atom DMD simulations ofwild-type SOD1 in the pres-
ence and absence of these stabilizing elements. Coordination of
metals contributes more to thermodynamic stability than does the
native disulfide bond, while both disulfide reduction and metal
loss lead to loss of intersubunit contacts important to dimer stability.
The reduced dimer stability of metal-free, disulfide-reduced SOD1
can be explained by the observation of increased flexibility in the
Glu-49-Asn-53 loop and resultant weakening of intersubunit con-
tacts. In addition to elucidating the contribution of native post-
translational modifications to SOD1 stability, MD simulations have
also enabled characterization of the structural consequences of
two modifications reported to be abundant in SOD1 from human
tissue: Thr-2 phosphorylation and Cys-111 glutathionylation
(Wilcox et al., 2009). In simulations utilizing all-atom DMD with
replica exchange, Proctor et al. (2011) report that both modifica-
tions, individually and in combination, destabilize dimers of wild-
type and mutant SOD1 and increase the energetic favorability of
populating a misfolded intermediate state.
a-synuclein and Parkinson’s disease
a-synuclein is a neuronal protein that plays a central role in
Parkinson’s disease (PD) and dementia with Lewy bodies, as well
as other neurodegenerative diseases such as AD and multiple
system atrophy (Jellinger, 2009; Breydo et al., 2012). PD involves
massive death of dopaminergic neurons in the substantia nigra,
leading to reduction of striatal dopamine levels and motor dysfunc-
tions such as tremor, rigidity of the limbs and trunk, bradykinesia,
and postural instability (Ferrer et al., 2012). Mutations in the gene
encodinga-synuclein (SNCA, also known as PARK1) corresponding
to A30P, E46K, and A53T substitutions have been discovered in
patients with early onset familial PD (Figure 2D), and evidence sug-
gests that these mutations promote a-synuclein aggregation
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(Breydo et al., 2012). Like Ab, a-synuclein is an intrinsically disor-
dered protein that forms morphologically diverse aggregates, in-
cluding spherical or ring-like oligomers, amorphous aggregates,
and amyloid fibrils (Breydo et al., 2012). Toxic oligomers also
may be released and sequestered by fibrils (Cremades et al., 2012).
As in several other protein conformational disorders, multiple
cytotoxic mechanisms have been proposed for a-synuclein mono-
mers and aggregates. a-synuclein oligomers induce oxidative
stress in neurons (Cremades et al., 2012) and can bind to lipid mem-
branes, permeabilizing bilayers, and sometimes forming ion-
conducting pores (Breydo et al., 2012). A detailed review of oligo-
mer toxicity was recently presented (Kalia et al., 2013).
Mechanisms of a-synuclein aggregate neurotoxicity include im-
pairment of a-synuclein degradation via proteasome inhibition
by the aggregated species, as well as copper-dependent gener-
ation of reactive oxygen species (Breydo et al., 2012; Zhou et al.,
2012). a-synuclein aggregation is also reported to underlie inflam-
mation and immune abnormalities present in PD, including aber-
rant microglial activation (Bennett, 2005).
Computer simulations have been instrumental in analysis of
a-synuclein structure and interactions, both of the native state and
of pathological aggregates. Simulations coupled with NMR
(Dedmon et al., 2005; Bortolus et al., 2008; Allison et al., 2009;
Wu et al., 2009) and FRET experiments (Nath et al., 2012) provided
evidence that the native state of a-synuclein is more compact than
would be expected for a random coil, and that it forms transient oli-
gomeric structures mediated by contacts made by the C-terminus. In
implicit solvent Monte Carlo simulations (Jónsson et al., 2012), two-
phase behavior of a-synuclein was observed in solution: one phase
is structurally disordered and another has significant b-strand
content. Destabilization of the native state is promoted by
disease-associated mutations, as was shown in MD studies for
A53T (Coskuner and Wise-Scira, 2013), A30P (Wise-Scira et al.,
2013a), and E46K (Wise-Scira et al., 2013b). Structural changes pro-
moted by these mutations result in more open states, biased to ag-
gregation (Hazy et al., 2011). Results of atomistic simulations
(Tsigelny et al., 2008) suggest that the transient oligomers formed
by a-synuclein may be the species capable of interacting with lipid
membranes. A MD study of aggregation kinetics (Matthes et al.,
2012) indicates a two-phase process of fibril formation, where for-
mation of the contact interface by mostly disordered chains is fol-
lowed by structural transition and accumulation of b-sheet
content. It also suggests a critical role of protein–solvent interac-
tions in a-synuclein aggregation. Structures of fibrils have also
been a focus of computer-assisted studies. Fibril rupture simulations
agree with AFM experiments and indicate the presence of highly
mechanically stable structures in a-synuclein fibrils with high
b-sheet content (Jónsson et al., 2013).
Concluding remarks
Protein aggregation has been implicated in numerous neuro-
degenerative disorders whose etiologies are poorly understood
and for which there are no effective treatments. In particular,
early-stage soluble oligomers are thought more likely to be
toxic, but their heterogeneity and/or transience often precludes
experimental characterization that could allow the development
of strategies to prevent their assembly or toxicity. Therefore,
the high-resolution structural, dynamic, and mechanistic insights
afforded by computational studies of protein aggregation have a
unique potential to enable the rational manipulation of oligomer
formation. Such capability will facilitate further direct testing of
the ‘cytotoxic oligomer hypothesis’ and reveal potential strat-
egies for inhibiting formation of toxic oligomers in neurodegen-
erative disorders.
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